HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Octreotide
ctreotide · DARAMONOL · GMP(CFDA) · OXTREOTIDE · Longastatin · Octreotide acetate · Octreotode Acetate · Ocetreotide, Acetate
Identifikatoren & physikalische Daten
| CAS No. | 83150-76-9 |
|---|---|
| Summenformel | C49H66N10O10S2 |
| Durchschnittliche Molmasse | 1.019,2 g/mol |
| Monoisotopische Masse | 1.018,44048031 g/mol |
| SMILES | C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O |
| InChIKey | DEQANNDTNATYII-OULOTJBUSA-N |
| PubChem CID | 448601 |
| ChEMBL | CHEMBL1680 |
| DTXSID | DTXSID0048682 |
Chemische & physikalische Eigenschaften
| XLogP | 1 |
|---|---|
| Polarare Oberfläche (TPSA) | 383 |
| H-Brücken-Donoren | 13 |
| H-Brücken-Akzeptoren | 14 |
| Frei drehbare Bindungen | 17 |
| Schwere Atome | 71 |
| Formalladung | 0 |
| Komplexität | 1.740 |
| Human Drugs | Breast FeedingLactationMilk, HumanAntineoplastic Agents, HormonalGastrointestinal AgentsEMA approved medicines: Human medicineMedicines for disorders of the pituitary hormone system |
| Schmelzpunkt | 153-156>140°C (dec.) |
| Siedepunkt | 1447.2±65.0 °C(Predicted) |
| Dichte | 1.39±0.1 g/cm3(Predicted) |
| Lagerbedingungen | -20°C |
| Löslichkeit | Soluble in acetic acid, DMSO, and methanolSoluble to 1.20 mg/ml in water |
| pKa (Säurekonstante) | 12.60±0.70(Predicted) |
| Aggregatzustand | Solid |
| Farbe | White to Off-White |
| Stabilität | Hygroscopic |
| InChIKey | DEQANNDTNATYII-MEUDYGGUSA-N |
| CAS Datenbank | 83150-76-9 |
Sicherheit & Vorschriften
| Regulatorische Informationen | Octreotide: Does not have an individual approval but may be used under an appropriate group standard |
|---|---|
| Hepatotoxicity | Mild, transient, asymptomatic elevations in serum aminotransferase levels occur in a small proportion of patients receiving octreotide, and in some individuals the elevations are persistent and worsen over time and may require drug discontinuation. In addition, several instances of acute, clinically apparent liver injury attributable to octreotide have been described. The onset is generally within 1 to 6 months of starting therapy and injury may be more frequent with higher doses. Most cases of liver injury associated with octreotide therapy have been asymptomatic and anicteric, and marked by prominent elevations in serum ALT and AST with normal or near normal serum alkaline phosphatase, GGT and bilirubin. In some instances, however, jaundice has arisen, particularly with rechallenge. There have been no instances of acute liver failure or vanishing bile duct syndrome associated with octreotide, and a characteristic feature of the injury is the rapidity of improvement upon stopping the injections or infusions. Several instances of marked aminotransferase elevations with rapid improvements on stopping have been reported in newborns and infants with congenital hyperinsulinemia who were treated with continuous infusions of high doses of octreotide. |
| Unerwünschte Wirkungen | * Gastrointestinal abnormalities (34% to 61%) are transient and usually mild to moderate. They include diarrhea, nausea, abdominal discomfort, gallbladder abnormalities, such as cholelithiasis and microlithiasis, biliary sediment and sludge due to alteration of fat absorption, and possibly by decreasing motility of the gallbladder. |
| Toxizitätsübersicht | Limited studies have assessed octreotide toxicity. However, isolated studies have shown a mild degree of bone marrow suppression and impairment in spermatogenesis due to inhibition of serum inhibin B and concomitant increase in FSH in supratherapeutic doses. There is a need to conduct significantly larger studies and trials to define and establish the therapeutic index of octreotide and identify its toxic effects and its management. |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)octreotideDILI PositiveIntravenousDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| Wassergefährdungsklasse (WGK) | 3 |
Anwendungen & Verwendung
Beschreibung
Octreotide is a long-acting somatostatin analog indicated for symptomatic control in acromegaly and gastroenteropancreatic tumors. Other potential uses under investigation include diabetes, psoriasis and Alzheimer's disease.
Verwenden
Octreotide Acetate is the acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. It inhibits the secretion of growth hormone, glucagon, insulin, gastrin, vasoactive intestinal peptide, secretin, motilin and pancreatic polypeptide. Octreotide acetate was uses for the treatment of severe diarrhea and flushing associated with malignant carcinoid tumors, acromegaly, and diarrhea associated with VIPoma; and, then in 2010, for the treatment of neuroendocrine tumors.